Cargando…

In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing Klebsiella pneumoniae: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations

Ceftazidime/avibactam uniquely demonstrates activity against both KPC and OXA-48-like carbapenemase-expressing Enterobacterales. Clinical resistance to ceftazidime/avibactam in KPC-producers was foreseen in in-vitro resistance studies. Herein, we assessed the resistance selection propensity of cefta...

Descripción completa

Detalles Bibliográficos
Autores principales: Palwe, Snehal, Bakthavatchalam, Yamuna Devi, Khobragadea, Kshama, Kharat, Arun S., Walia, Kamini, Veeraraghavan, Balaji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8614831/
https://www.ncbi.nlm.nih.gov/pubmed/34827256
http://dx.doi.org/10.3390/antibiotics10111318
_version_ 1784603956403503104
author Palwe, Snehal
Bakthavatchalam, Yamuna Devi
Khobragadea, Kshama
Kharat, Arun S.
Walia, Kamini
Veeraraghavan, Balaji
author_facet Palwe, Snehal
Bakthavatchalam, Yamuna Devi
Khobragadea, Kshama
Kharat, Arun S.
Walia, Kamini
Veeraraghavan, Balaji
author_sort Palwe, Snehal
collection PubMed
description Ceftazidime/avibactam uniquely demonstrates activity against both KPC and OXA-48-like carbapenemase-expressing Enterobacterales. Clinical resistance to ceftazidime/avibactam in KPC-producers was foreseen in in-vitro resistance studies. Herein, we assessed the resistance selection propensity of ceftazidime/avibactam in K. pneumoniae expressing OXA-48-like β-lactamases (n = 10), employing serial transfer approach. Ceftazidime/avibactam MICs (0.25–4 mg/L) increased to 16–256 mg/L after 15 daily-sequential transfers. The whole genome sequence analysis of terminal mutants showed modifications in proteins linked to efflux (AcrB/AcrD/EmrA/Mdt), outer membrane permeability (OmpK36) and/or stress response pathways (CpxA/EnvZ/RpoE). In-vitro growth properties of all the ceftazidime/avibactam-selected mutants were comparable to their respective parents and they retained the ability to cause pulmonary infection in neutropenic mice. Against these mutants, we explored the activities of various combinations of β-lactams (ceftazidime or cefepime) with structurally diverse β-lactamase inhibitors or a β-lactam enhancer, zidebactam. Zidebactam, in combination with either cefepime or ceftazidime, overcame ceftazidime/avibactam resistance (MIC range 0.5–8 mg/L), while cefepime/avibactam was the second best (MIC: 0.5–16 mg/L) in yielding lower MICs. The present work revealed the possibility of ceftazidime/avibactam resistance in OXA-48-like K. pneumoniae through mutations in proteins involved in efflux and/or porins without concomitant fitness cost mandating astute monitoring of ceftazidime/avibactam resistance among OXA-48 genotypes.
format Online
Article
Text
id pubmed-8614831
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86148312021-11-26 In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing Klebsiella pneumoniae: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations Palwe, Snehal Bakthavatchalam, Yamuna Devi Khobragadea, Kshama Kharat, Arun S. Walia, Kamini Veeraraghavan, Balaji Antibiotics (Basel) Article Ceftazidime/avibactam uniquely demonstrates activity against both KPC and OXA-48-like carbapenemase-expressing Enterobacterales. Clinical resistance to ceftazidime/avibactam in KPC-producers was foreseen in in-vitro resistance studies. Herein, we assessed the resistance selection propensity of ceftazidime/avibactam in K. pneumoniae expressing OXA-48-like β-lactamases (n = 10), employing serial transfer approach. Ceftazidime/avibactam MICs (0.25–4 mg/L) increased to 16–256 mg/L after 15 daily-sequential transfers. The whole genome sequence analysis of terminal mutants showed modifications in proteins linked to efflux (AcrB/AcrD/EmrA/Mdt), outer membrane permeability (OmpK36) and/or stress response pathways (CpxA/EnvZ/RpoE). In-vitro growth properties of all the ceftazidime/avibactam-selected mutants were comparable to their respective parents and they retained the ability to cause pulmonary infection in neutropenic mice. Against these mutants, we explored the activities of various combinations of β-lactams (ceftazidime or cefepime) with structurally diverse β-lactamase inhibitors or a β-lactam enhancer, zidebactam. Zidebactam, in combination with either cefepime or ceftazidime, overcame ceftazidime/avibactam resistance (MIC range 0.5–8 mg/L), while cefepime/avibactam was the second best (MIC: 0.5–16 mg/L) in yielding lower MICs. The present work revealed the possibility of ceftazidime/avibactam resistance in OXA-48-like K. pneumoniae through mutations in proteins involved in efflux and/or porins without concomitant fitness cost mandating astute monitoring of ceftazidime/avibactam resistance among OXA-48 genotypes. MDPI 2021-10-29 /pmc/articles/PMC8614831/ /pubmed/34827256 http://dx.doi.org/10.3390/antibiotics10111318 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Palwe, Snehal
Bakthavatchalam, Yamuna Devi
Khobragadea, Kshama
Kharat, Arun S.
Walia, Kamini
Veeraraghavan, Balaji
In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing Klebsiella pneumoniae: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations
title In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing Klebsiella pneumoniae: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations
title_full In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing Klebsiella pneumoniae: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations
title_fullStr In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing Klebsiella pneumoniae: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations
title_full_unstemmed In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing Klebsiella pneumoniae: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations
title_short In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing Klebsiella pneumoniae: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations
title_sort in-vitro selection of ceftazidime/avibactam resistance in oxa-48-like-expressing klebsiella pneumoniae: in-vitro and in-vivo fitness, genetic basis and activities of β-lactam plus novel β-lactamase inhibitor or β-lactam enhancer combinations
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8614831/
https://www.ncbi.nlm.nih.gov/pubmed/34827256
http://dx.doi.org/10.3390/antibiotics10111318
work_keys_str_mv AT palwesnehal invitroselectionofceftazidimeavibactamresistanceinoxa48likeexpressingklebsiellapneumoniaeinvitroandinvivofitnessgeneticbasisandactivitiesofblactamplusnovelblactamaseinhibitororblactamenhancercombinations
AT bakthavatchalamyamunadevi invitroselectionofceftazidimeavibactamresistanceinoxa48likeexpressingklebsiellapneumoniaeinvitroandinvivofitnessgeneticbasisandactivitiesofblactamplusnovelblactamaseinhibitororblactamenhancercombinations
AT khobragadeakshama invitroselectionofceftazidimeavibactamresistanceinoxa48likeexpressingklebsiellapneumoniaeinvitroandinvivofitnessgeneticbasisandactivitiesofblactamplusnovelblactamaseinhibitororblactamenhancercombinations
AT kharataruns invitroselectionofceftazidimeavibactamresistanceinoxa48likeexpressingklebsiellapneumoniaeinvitroandinvivofitnessgeneticbasisandactivitiesofblactamplusnovelblactamaseinhibitororblactamenhancercombinations
AT waliakamini invitroselectionofceftazidimeavibactamresistanceinoxa48likeexpressingklebsiellapneumoniaeinvitroandinvivofitnessgeneticbasisandactivitiesofblactamplusnovelblactamaseinhibitororblactamenhancercombinations
AT veeraraghavanbalaji invitroselectionofceftazidimeavibactamresistanceinoxa48likeexpressingklebsiellapneumoniaeinvitroandinvivofitnessgeneticbasisandactivitiesofblactamplusnovelblactamaseinhibitororblactamenhancercombinations